Announcements Trials
Browse Landscape

Phase

Phase NA 15Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Other hematologic neoplasm 3Lymphoid 2Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Hematopoietic and Lymphatic System Neoplasm 1

Interventions

Carboplatin 10Cisplatin 7Pemetrexed 6Vincristine 5Nivolumab 5Etoposide 4Topotecan 3Specimen Handling 3Ipilimumab 3Injections 3Doxorubicin 3Talc 2Radiotherapy 2Paclitaxel 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1sintilimab 1ranpirnase 1raltitrexed 1pertuzumab 1pembrolizumab 1onartuzumab 1iniparib 1durvalumab 1dostarlimab 1crofelemer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Practice Guidelines as Topic × Other solid neoplasm × Clear all
NCT06513962 2026-05-05

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Children's Oncology Group

Phase 3 Recruiting
60 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡